New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MRK;PFE;GSK;JNJ;BMY;NVS;SHPG;ABT;CELG;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 20, 2015
11:44 EDTNVSCAR-T therapy stocks fall following cancer research meeting
Subscribe for More Information
09:20 EDTNVS, SNYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
08:12 EDTBMYVanda names Tom Gibbs as SVP and Chief Commercial OfficerBristol-Myers
Subscribe for More Information
08:05 EDTMRKTetraLogic, Merck enter into oncology clinical study collaboration
Subscribe for More Information
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
07:20 EDTGSK, MRK, NVS, BMYAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:18 EDTNVSAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
07:01 EDTGSKPernix Therapeutics obtains six months U.S. pediatric exclusivity for Treximet
Subscribe for More Information
06:59 EDTJNJJohnson & Johnson added to short-term buy list at Deutsche Bank
Subscribe for More Information
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
April 19, 2015
19:35 EDTMRKMerck to swiftly repay $5B loan, explore acquisitions by late 2017, Reuters says
Subscribe for More Information
15:21 EDTMRKMerck announces new data from Keytruda study
Subscribe for More Information
14:59 EDTMRKMerck's Keytruda 'superior' to ipilimumab for PFS in patients with melanoma
Subscribe for More Information
14:47 EDTMRKMerck submits supplemental biologics license for Keytruda in lung cancer
Subscribe for More Information
14:31 EDTMRKMerck reports 28% Keytruda response rate in 25 pleural mesothelioma patients
Subscribe for More Information
April 17, 2015
16:31 EDTJNJStocks end week lower amid earnings reports, fear about Greece, China
Subscribe for More Information
09:41 EDTBMYBristol-Myers up after Phase III Opdivo study met endpoint, trial stopped early
Subscribe for More Information
09:36 EDTBMYActive equity options trading on open
Subscribe for More Information
09:08 EDTBMYBristol-Myers data should be positive, says SunTrust
SunTrust expects the AACR data for Bristol-Myers' CheckMate-069 Opdivo + Yervoy combo, a treatment for melanoma, to show a positive overall response rate and progressive free survival that exceeds its prior -0004 results. The firm notes that the data is due to be presented on April 20. It raised its 2020 Opdivo revenue estimate to $7.1B versus the Street's $6.9B and raised its price target o n he stock to $74 from $70 while keeping a Buy rating on the shares.
08:58 EDTBMYBristol-Myers jumps 4% after Opdivo study stopped early after meeting endpoint
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use